Patient Facing Nuclear Medicine

Phillip Koo | October 27, 2018

The field of nuclear medicine has seen a resurgence in relevance especially in the area of prostate cancer imaging and therapy.  Dr. Evan Yu adeptly summarizes the promising potential of PSMA radioligand therapies in his October 2018 post in the Clinical Trials section of UroToday.  We look forward to seeing his future article regarding diagnostic trials evaluating various PSMA targeted agents.


Phillip J. Koo, MD, FACS

Phillip J. Koo, MD is the Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. He is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine and is the Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging.

State-of-the-industry video lectures by leading urology experts
Everyday Urology - Oncology Insights
Publications focusing on urologic cancer treatments through original manuscripts
By Phillip J. Koo, MD
Experts at Harvard Business School first coined the term disruptive innovation to describe how small, poorly resourced companies could successfully challenge larger ones.1 More than two decades later, this concept is central in medicine, where innovations in everything from proteomics and wearables to electronic health records and health economics are upending our status quo.2,41 Many of these disruptors are exciting—they aim to advance diagnostics, treatment, outcomes, and multidisciplinary patient-centered care. But they come with risks, too: Their popularity can outpace their efficacy and safety, and they can impede clinical workflows.3,4
By Karen E. Linder, MS, PHD
Prostate cancer [PCa] affects 1 man in 7 in the United States, making this the most commonly diagnosed non-cutaneous cancer in males.  Although an ever-increasing number of treatment options exist, an estimated 26,100 men will still die of the disease in the US in 2016, generally after primary local and systemic treatments for prostate cancer have failed.  One factor contributing to this statistic is the frequent inability of current diagnostic methods to reliably detect the exact location(s) of disease relapse at a time when curative treatment is still possible.  
Conference Coverage
Recent data from conferences worldwide
Presented by Stefano Fanti, MD
Barcelona, Spain ( Theranostics is an emerging field of medicine which utilizes targeted cancer therapy based on specific molecular-targeted diagnostic tests. As part of the Imaging in Prostate Cancer plenary session
Presented by Olivier Rouvière, MD, PhD
Barcelona, Spain ( Dr. Rouviere presented the imaging specialist’s perspective on MRI use in prostate cancer. According to the European Association of Urology (EAU) guidelines prostate multiparametric MRI
Presented by Michael Hofman, FRACP, MBBS
San Francisco, CA ( PSMA is over-expressed in all prostate tissue, including prostatic carcinoma. Lutetium-177 (177Lu)-PSMA617 (LuPSMA) is a small radiolabeled molecule which binds to PSMA
Presented by Jeremie Calais, MD, MSc
San Francisco, CA (  Salvage radiotherapy (SRT) for prostate cancer biochemical recurrence after radical prostatectomy (RP) is commonly administered to patients
Presented by Paul L. Nguyen, MD
Prague, Czech Republic ( Dr. Paul Nguyen took the stance for radiation therapy in this much-anticipated debate regarding appropriate local treatment in men with high risk localized prostate cancer

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.